Esketamine (Spravato) vs racemic ketamine for depression — FDA status, insurance coverage, cost, setting, and which to pick when.
Choosing between Spravato vs ketamine is mostly a choice about approval, insurance, and where you get treated. Spravato is the brand name for esketamine, an FDA-approved nasal spray. Racemic ketamine is the older, generic drug given by IV infusion or as an at-home lozenge. Both can ease depression fast, but they differ in cost, coverage, and setting. This guide compares them side by side so you can see which fits your situation today.
Spravato is the better fit if you want an FDA-approved option with a real chance at insurance coverage. Ketamine infusions and at-home lozenges give you more dosing flexibility and often a lower cash price, but they are used off-label and rarely covered. For most people with treatment-resistant depression, the deciding factors are what your insurance pays for and how much monitoring you want.
| Factor | Spravato (esketamine) | Racemic ketamine |
|---|---|---|
| FDA status | FDA-approved for treatment-resistant depression; standalone use approved January 2025. | Not FDA-approved for depression. Used off-label (approved only as an anesthetic). |
| What it is | The esketamine (S) half of the ketamine molecule. | A 50/50 racemic mix of esketamine (S) and arketamine (R). |
| How you take it | Nasal spray (56 mg or 84 mg), self-administered under supervision. | IV infusion in-clinic, or an at-home oral lozenge via telehealth. |
| Dosing flexibility | Fixed, standardized doses set by the label. | Dose, infusion rate, and session count adjusted to the patient. |
| Insurance coverage | Often covered by commercial insurance and Medicare for eligible patients. | Usually self-pay; insurance rarely covers it. |
| Typical cost | ~$600–$900 per session before insurance; far less with coverage. | ~$400–$800 per IV session; ~$150–$400/month for at-home lozenges. |
| Where it happens | Certified clinic only, with ~2 hours of monitoring (REMS program). | IV in-clinic; lozenges taken at home after a telehealth evaluation. |
Spravato and ketamine are closely related but not the same. Ketamine is a racemic mixture, which means it contains two mirror-image molecules in equal parts: esketamine (the "S" form) and arketamine (the "R" form). Spravato is purified esketamine only. In other words, Spravato is one specific half of the ketamine molecule, packaged as a branded nasal spray.
Esketamine binds the NMDA glutamate receptor more tightly than the racemic mix.1 That higher potency is part of why a drug company could study it, patent it, and win FDA approval. Racemic ketamine is generic and cannot be patented, so no company has funded the large trials needed to get it approved for depression. You can read more in our full ketamine guide.
Some researchers argue the arketamine (R) form in racemic ketamine may add its own antidepressant effect, and studies of it are ongoing. Others point to esketamine's stronger receptor binding as an advantage. For now, the honest answer is that both forms help many people, and no head-to-head trial has clearly crowned one as better for every patient.
Both Spravato and racemic ketamine can lift depression within hours to days, which is far faster than standard antidepressants. Their evidence bases differ mainly in how they were studied and approved.
Spravato has the formal regulatory record. The FDA first approved it in 2019 for treatment-resistant depression alongside an oral antidepressant. In January 2025, the FDA approved it as the first standalone (monotherapy) treatment for treatment-resistant depression, so patients no longer need to pair it with a daily pill.2 Because it is a branded product, its dosing and monitoring are tightly standardized.
Racemic ketamine has a longer real-world track record and a large body of trial data for depression, even without FDA approval for that use. A single sub-anesthetic dose can reduce symptoms within hours.3 Clinicians value its flexibility: they can adjust the dose, the infusion rate, and how many sessions you get. The trade-off is that "off-label" means less standardization and, usually, no insurance coverage.
This is where the two options split most clearly for real budgets. Spravato often qualifies for insurance, which can make it cheaper out of pocket despite a higher sticker price. Ketamine usually does not.
So the "cheaper" option depends on your coverage. With good insurance, Spravato can cost less than cash-pay ketamine. Without it, at-home ketamine is often the lowest-cost entry point. Not sure which path fits your goals? Try our depression treatment path tool to compare your real options, or see our full breakdown of how much ketamine therapy costs.
Both drugs are given under medical supervision, but the settings differ. Spravato can only be taken in a certified healthcare setting under a federal safety program called REMS. You self-spray the medication, then stay for about two hours of monitoring before someone drives you home. You cannot take it at home.
Racemic ketamine has more setting options. IV infusions happen in a clinic with staff present. At-home lozenges are prescribed through telehealth and taken in your own space, which adds convenience but less direct supervision. Quality varies a lot across telehealth providers, so look for a real psychiatric evaluation, not a quick online form.
Screening matters for both. A good provider reviews your medical history, current medications, blood pressure, and mental health before you start. People with uncontrolled blood pressure, certain heart conditions, or a history of psychosis may not be good candidates. See our at-home ketamine safety checklist if you are considering the telehealth route.
Depression is the strongest use case for both. Spravato is specifically approved for treatment-resistant depression and for depressive symptoms with acute suicidal thoughts (still paired with an oral antidepressant in that case). Racemic ketamine is used off-label for treatment-resistant depression and, in some clinics, for anxiety, PTSD, and chronic pain. If you are comparing ketamine to other paths entirely, see our ketamine vs antidepressants and ketamine vs psilocybin guides.
Choose Spravato if you want an FDA-approved treatment, value standardized dosing and clinic monitoring, and have insurance that may cover it. It is the option with the clearest regulatory backing for treatment-resistant depression.
Choose racemic ketamine if you want flexible dosing, prefer the lower cash price of at-home lozenges or IV infusions, or your clinician recommends a tailored infusion plan. It trades FDA approval and coverage for flexibility and, often, a lower out-of-pocket entry cost.
Still unsure which route matches your situation? Our depression treatment path tool walks through legal access, cost, and evidence for each option, or you can find a ketamine provider to discuss both.
No, but they are closely related. Ketamine is a racemic mixture of two mirror-image molecules: esketamine (the S form) and arketamine (the R form). Spravato is purified esketamine only, delivered as a branded nasal spray. So Spravato is one specific half of the ketamine molecule, not a different drug and not the whole molecule.
Spravato is far more likely to be covered. Because it is FDA-approved for treatment-resistant depression, commercial insurance and Medicare often cover it for eligible patients, and the maker runs a copay savings program. Racemic ketamine infusions and at-home lozenges are used off-label, so insurance rarely covers them and most patients pay out of pocket.
Spravato's list price runs roughly $600 to $900 per session plus a clinic monitoring fee, but insurance can cut that a lot. IV ketamine infusions cost about $400 to $800 each and are usually self-pay, while at-home ketamine lozenges run about $150 to $400 per month. With good coverage Spravato can be cheaper; without it, at-home ketamine is often the lowest-cost option.
No. Spravato can only be taken in a certified healthcare setting under a federal safety program called REMS. You self-spray the medication, then stay about two hours for monitoring before someone drives you home. At-home ketamine lozenges are prescribed through telehealth and taken in your own space, which is more convenient but has less direct supervision.
No head-to-head trial has clearly shown one is better for every patient. Esketamine binds the NMDA receptor more tightly, and Spravato has formal FDA approval and standardized dosing. Racemic ketamine offers flexible, individualized dosing and a long real-world track record. Both help many people; the right choice usually depends on coverage, setting, and your clinician's judgment.
Yes, in most cases. In January 2025 the FDA approved Spravato as a standalone (monotherapy) treatment for treatment-resistant depression, so it no longer must be paired with a daily oral antidepressant. One exception remains: for depressive symptoms with acute suicidal thoughts, it is still used alongside an oral antidepressant.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.